Influence of patient and tumor characteristics on therapy persistence with letrozole in postmenopausal women with advanced breast cancer: results of the prospective observational EvAluate-TM study

Journal article


Publication Details

Author(s): Wallwiener M, Nabieva N, Feisst M, Fehm T, De Waal J, Rezai M, Baier B, Baake G, Kolberg HC, Guggenberger M, Warm M, Harbeck N, Wuerstlein R, Deuker JU, Dall P, Richter B, Wachsmann G, Brucker C, Siebers JW, Popovic M, Kuhn T, Wolf C, Vollert HW, Breitbach GP, Janni W, Landthaler R, Kohls A, Rezek D, Noesselt T, Fischer G, Henschen S, Praetz T, Heyl V, Kuehn T, Krauss T, Thomssen C, Hohn A, Tesch H, Mundhenke C, Hein A, Rauh C, Bayer CM, Schmidt K, Belleville E, Brucker SY, Hadji P, Beckmann M, Wallwiener D, Kuemmel S, Hartkopf A, Fasching P
Journal: BMC Cancer
Publication year: 2019
Volume: 19
ISSN: 1471-2407


Abstract

BackgroundTreatment of postmenopausal, hormone receptor-positive metastatic breast cancer (MBC) patients varies despite clear therapy guidelines, favoring endocrine treatment (ET). Aim of this study was to analyze persistence of palliative aromatase inhibitor (AI) monotherapy in MBC patients.MethodsEvAluate-TM is a prospective, multicenter, noninterventional study to evaluate treatment with letrozole in postmenopausal women with hormone receptor-positive breast cancer. To assess therapy persistence, defined as the time from therapy start to the end of the therapy (TTEOT), two pre-specified study visits took place after 6 and 12months. Competing risk survival analyses were performed to identify patient and tumor characteristics that predict TTEOT.ResultsOut of 200 patients, 66 patients terminated treatment prematurely, 26 (13%) of them due to causes other than disease progression. Persistence rate for reasons other than progression at 12months was 77.7%. Persistence was lower in patients who reported any adverse event (AE) in the first 30days of ET (89.5% with no AE and 56% with AE). Furthermore, patients had a lower persistence if they reported compliance problems in the past before letrozole treatment.ConclusionsDespite suffering from a life-threatening disease, AEs of an AI will result in a relevant number of treatment terminations that are not related to progression. Some subgroups of patients have very low persistence rates. Especially with regard to novel endocrine combination therapies, these data imply that some groups of patients will need special attention to guide them through the therapy process.Trial registrationClinical Trials Number: CFEM345DDE19


FAU Authors / FAU Editors

Beckmann, Matthias Prof. Dr.
Lehrstuhl für Geburtshilfe und Frauenheilkunde
Fasching, Peter PD Dr.
Professur für Translationale Frauenheilkunde und Geburtshilfe
Hein, Alexander PD Dr.
Frauenklinik
Nabieva, Naiba Dr. med.
Frauenklinik


External institutions with authors

Asklepios Klinik Wiesbaden GmbH
Caritas-Krankenhaus Bad Mergentheim gemeinnützige GmbH
Centrum für Hämatologie und Onkologie Bethanien
ClinSol GmbH & Co.KG
Diakonie-Klinikum Stuttgart Diakonissenkrankenhaus und Paulinenhilfe gGmbH
Eberhard Karls Universität Tübingen
Elblandkliniken
Evangelisches Krankenhaus Ludwigsfelde-Teltow
Heinrich-Heine-Universität Düsseldorf
Johanniter-Krankenhaus Genthin-Stendal
Klinikum Bayreuth
Klinikum der Universität München (Großhadern und Innenstadt)
Klinikum Friedrichshafen
Klinikum Landkreis Tuttlingen
Krankenhaus Nordwest
Kreisklinik Günzburg Krumach
Landkreis Mittweida Krankenhaus
Luisenkrankenhaus Düsseldorf
Marien-Hospital
Marienhospital Bottrop
Martin-Luther-Universität Halle-Wittenberg (MLU)
Medizinisches Zentrum Ulm
Novartis Pharma Germany
Onkologische Praxis Pinneberg
Paracelsus Medizinische Privatuniversität
Ruprecht-Karls-Universität Heidelberg
Sana Klinikum Hameln-Pyrmont
Städtisches Klinikum Lüneburg
Städtisches Klinikum Neunkirchen
Städtisches Krankenhaus Kiel
Universitätsklinikum Köln
Universitätsklinikum Schleswig-Holstein (UKSH)
Universitätsklinikum Ulm
Vinzenzkrankenhaus Hannover GmbH


How to cite

APA:
Wallwiener, M., Nabieva, N., Feisst, M., Fehm, T., De Waal, J., Rezai, M.,... Fasching, P. (2019). Influence of patient and tumor characteristics on therapy persistence with letrozole in postmenopausal women with advanced breast cancer: results of the prospective observational EvAluate-TM study. BMC Cancer, 19. https://dx.doi.org/10.1186/s12885-019-5806-y

MLA:
Wallwiener, Markus, et al. "Influence of patient and tumor characteristics on therapy persistence with letrozole in postmenopausal women with advanced breast cancer: results of the prospective observational EvAluate-TM study." BMC Cancer 19 (2019).

BibTeX: 

Last updated on 2019-11-07 at 09:08